1
|
Harbour SN, Mitchell HM, Sutton P. Host Nonresponsiveness Does not Interfere With Vaccine-Mediated Protection Against Gastric Helicobacter Infection. Helicobacter 2015; 20:217-22. [PMID: 25683672 DOI: 10.1111/hel.12197] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Helicobacter pylori pathogenesis results from the inflammation induced by chronic infection. CBA mice are nonresponsive to gastric Helicobacter infection, providing a useful model for examining host regulation of Helicobacter-induced gastritis. We examined whether gastric Helicobacter nonresponsiveness impacts upon vaccine efficacy and whether immune-mediated protection could occur in the absence of inflammation. METHODS Mice were vaccinated prior to challenge with Helicobacter felis or H. pylori. Gastritis and H. felis colonization was evaluated histologically. H. pylori colonization was quantified by colony-forming assay. RESULTS Immunizations protected CBA mice against challenge with either H. felis or H. pylori. Protection against H. felis was marked by a loss of nonresponsiveness and development of an atrophic gastritis with mucus metaplasia. However, vaccine-induced protection against H. pylori was only associated with cell infiltration into the gastric mucosa. CONCLUSIONS Nonresponsiveness to gastric Helicobacter infection did not interfere with vaccination-induced protection. Vaccine-induced protective immunity against H. pylori was linked with the induction of cellular infiltration, but importantly not atrophic gastritis.
Collapse
Affiliation(s)
- Stacey N Harbour
- Centre for Animal Biotechnology, School of Veterinary Science, University of Melbourne, Parkville, Vic., 3010, Australia
| | - Hazel M Mitchell
- School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, 2052, Australia
| | - Philip Sutton
- Centre for Animal Biotechnology, School of Veterinary Science, University of Melbourne, Parkville, Vic., 3010, Australia.,Mucosal Immunology, Murdoch Childrens Research Institute, Royal Children's Hospital, Parkville, VIC., 3052, Australia
| |
Collapse
|
2
|
Chionh YT, Arulmuruganar A, Venditti E, Ng GZ, Han JX, Entwisle C, Ang CS, Colaco CA, McNulty S, Sutton P. Heat shock protein complex vaccination induces protection against Helicobacter pylori without exogenous adjuvant. Vaccine 2014; 32:2350-8. [PMID: 24625340 DOI: 10.1016/j.vaccine.2014.02.051] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2013] [Revised: 01/24/2014] [Accepted: 02/12/2014] [Indexed: 12/18/2022]
Abstract
BACKGROUND The development of a vaccine against the human gastric pathogen Helicobacter pylori, the main causative agent of gastric adenocarcinoma, has been hampered by a number of issues, including the lack of a mucosal adjuvant for use in humans. Heat shock proteins (Hsp), highly conserved molecules expressed by both bacteria and mammalian species, possess a range of functions, including acting as chaperones for cellular proteins and the ability to activate innate immune receptors. Hsp complex (HspC) vaccines, containing Hsp derived from pathogenic bacteria, are immunostimulatory without addition of an exogenous adjuvant and can induce immunity against their chaperoned proteins. In this study we explored in mice the potential utility of a H. pylori HspC vaccine. RESULTS Vaccination with H. pylori HspC, by either the subcutaneous or respiratory mucosal route, induced a strong antibody response, elevated gastric cytokine levels and significant protection against subsequent live challenge with this pathogen. The level of protection induced by non-adjuvanted HspC vaccine was equivalent to that which resulted from vaccination with adjuvanted vaccines. While protection induced by immunisation with adjuvanted vaccines was associated with the development of a moderate to severe atrophic gastritis, that induced by H. pylori HspC only resulted in a mild inflammatory response, despite an increase in pro-inflammatory gastric cytokines. This reduced gastritis correlated with an increase in IL-10 and IL-13 levels in the gastric tissues of HspC vaccinated, H. pylori challenged mice. CONCLUSIONS H. pylori HspC vaccines have the potential to overcome some of the issues preventing the development of a human vaccine against this pathogen: HspC induced protective immunity against H. pylori without addition of an adjuvant and without the induction of a severe inflammatory response. However, complete protection was not obtained so further optimisation of this technology is needed if a human vaccine is to become a reality.
Collapse
Affiliation(s)
- Yok Teng Chionh
- Mucosal Immunology, Murdoch Childrens Research Institute, Royal Children's Hospital, Melbourne, Parkville, VIC 3052, Australia; Centre for Animal Biotechnology, School of Veterinary Science, University of Melbourne, Parkville, VIC 3010, Australia
| | - Arthi Arulmuruganar
- Mucosal Immunology, Murdoch Childrens Research Institute, Royal Children's Hospital, Melbourne, Parkville, VIC 3052, Australia
| | - Elena Venditti
- ImmunoBiology Ltd., Babraham Research Campus, Babraham, Cambridge, UK
| | - Garrett Z Ng
- Mucosal Immunology, Murdoch Childrens Research Institute, Royal Children's Hospital, Melbourne, Parkville, VIC 3052, Australia
| | - Jia-Xi Han
- Mucosal Immunology, Murdoch Childrens Research Institute, Royal Children's Hospital, Melbourne, Parkville, VIC 3052, Australia
| | - Claire Entwisle
- ImmunoBiology Ltd., Babraham Research Campus, Babraham, Cambridge, UK
| | - Ching-Seng Ang
- Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, VIC 3010, Australia
| | - Camilo A Colaco
- ImmunoBiology Ltd., Babraham Research Campus, Babraham, Cambridge, UK
| | - Shaun McNulty
- ImmunoBiology Ltd., Babraham Research Campus, Babraham, Cambridge, UK
| | - Philip Sutton
- Mucosal Immunology, Murdoch Childrens Research Institute, Royal Children's Hospital, Melbourne, Parkville, VIC 3052, Australia; Centre for Animal Biotechnology, School of Veterinary Science, University of Melbourne, Parkville, VIC 3010, Australia.
| |
Collapse
|
4
|
Every AL, Stent A, Moloney MB, Ng GZ, Skene CD, Edwards SJ, Sutton P. Evaluation of superoxide dismutase from Helicobacter pylori as a protective vaccine antigen. Vaccine 2010; 29:1514-8. [PMID: 21172379 DOI: 10.1016/j.vaccine.2010.12.019] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2010] [Revised: 12/02/2010] [Accepted: 12/03/2010] [Indexed: 12/17/2022]
Abstract
Helicobacter pylori, the major cause of gastric cancer, have mechanisms that allow colonization of the inhospitable gastric mucosa, including enzymes such as superoxide dismutase (SOD) which protect against reactive oxygen species. As SOD is essential for in vivo colonization, we theorized it might constitute a viable vaccine target. H. pylori SOD was expressed in E. coli and a purified recombinant protein used to vaccinate mice, prior to live H. pylori challenge. Partial protective immunity was induced, similar to that commonly observed with other antigens tested previously. This suggests SOD may have utility in a combination vaccine comprising several protective antigens.
Collapse
Affiliation(s)
- Alison L Every
- Centre for Animal Biotechnology, School of Veterinary Science, University of Melbourne, Parkville, VIC 3010, Australia
| | | | | | | | | | | | | |
Collapse
|